论文部分内容阅读
目的探讨多种肿瘤标志物蛋白芯片检测系统(C-12)在III期非小细胞肺癌的病情监测、治疗反应观察和预后评估中的意义。方法应用该芯片检测系统测定57例III期非小细胞肺癌病人化疗前后血清中12种肿瘤标志物(CA19-9,NSE,CEA,CA242,Fe,HCG,AFP,FPSA,PSA,CA125,HGH,CA15-3)的水平,观察化疗疗效与C-12的关系。结果57例病人中不同疗效组患者自身前后对照,其血清肿瘤标志物水平和C-12总阳性率无显著性差异;在剔除各组中C-12阴性病例后,PR组中的C-12阳性病人治疗后有CA19-9、CA15-3及Fe显著性降低(P<0.05),而NC组中的C-12阳性病人各项肿瘤标志物水平在化疗后均无明显变化。结论该检测系统在监测C-12阳性肺癌的治疗效果方面有一定的指导意义,如作适当改进,将能更有效地运用于临床。
Objective To investigate the significance of multiple tumor marker protein chip detection system (C-12) in the surveillance, response and prognosis evaluation of stage III non-small cell lung cancer. Methods The tumor detection of 12 tumor markers (CA19-9, NSE, CEA, CA242, Fe, HCG, AFP, FPSA, PSA, CA125 and HGH in 57 patients with stage III NSCLC before and after chemotherapy) CA15-3) levels, to observe the relationship between chemotherapy and C-12. Results There were no significant differences in the level of serum tumor markers and the positive rate of C-12 in 57 patients before and after treatment in different curative effect groups. After excluding C-12 negative cases in each group, C-12 The positive patients had significant reduction of CA19-9, CA15-3 and Fe after treatment (P <0.05), while the levels of tumor markers in C-12 positive patients in NC group had no significant changes after chemotherapy. Conclusion The detection system has certain guiding significance in monitoring the therapeutic effect of C-12 positive lung cancer. If it is properly improved, it will be more effectively used in clinical practice.